Immune cell biology
Biology of T cells, professional antigen presenting cells and other immune cell subsets; antigen processing and presentation
Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma
(1) Cohen AD (2) Lendvai N (3) Nataraj S (4) Imai N (5) Jungbluth AA (6) Tsakos I (7) Rahman A (8) Mei AH (9) Singh H (10) Zarychta K (11) Kim-Schulze S (12) Park AJ (13) Venhaus RR (14) Alpaugh RK (15) Gnjatic S (16) Cho HJ
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients
(1) Migliorini D (2) Dutoit V (3) Allard M (4) Hallez NG (5) Marinari E (6) Widmer V (7) Philippin G (8) Corlazzoli F (9) Gustave R (10) Kreutzfeldt M (11) Blazek N (12) Wasem J (13) Hottinger A (14) Koka A (15) Momjian S (16) Lobrinus A (17) Merkler D (18) Vargas MI (19) Walker PR (20) Patrikidou A (21) Dietrich PY
(1) Migliorini D (2) Dutoit V (3) Allard M (4) Hallez NG (5) Marinari E (6) Widmer V (7) Philippin G (8) Corlazzoli F (9) Gustave R (10) Kreutzfeldt M (11) Blazek N (12) Wasem J (13) Hottinger A (14) Koka A (15) Momjian S (16) Lobrinus A (17) Merkler D (18) Vargas MI (19) Walker PR (20) Patrikidou A (21) Dietrich PY
Author Info: (1) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (2) Laboratory of Tumor immunology and
Author Info: (1) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (2) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (3) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (4) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (5) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (6) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (7) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (8) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (9) Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland. (10) Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland. (11) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (12) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (13) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (14) Neurosurgery Division, Department of Neurosciences, Geneva University Hospital, Geneva, Switzerland. (15) Neurosurgery Division, Department of Neurosciences, Geneva University Hospital, Geneva, Switzerland. (16) Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland. (17) Neuropathology Division, Department of Pathology, Geneva University Hospital, Geneva, Switzerland. (18) Department of Imaging and Medical information Sciences, Neuroradiology Division, Geneva University Hospital, Geneva, Switzerland. (19) Laboratory of Tumor immunology, Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, & Division of Oncology, HUG, Geneva, Switzerland. (20) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. (21) Department of Oncology, Clinical Research Unit, Dr Dubois Ferriere Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland. Laboratory of Tumor immunology and Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Translational research center for oncohaematology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland.
Citation: Neuro Oncol 2019 Feb 12 Epub02/12/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30753611
An immunoproteomic approach to characterize the CAR interactome and signalosome
(1) Ramello MC (2) Benzaid I (3) Kuenzi BM (4) Lienlaf-Moreno M (5) Kandell WM (6) Santiago DN (7) Pabon-Saldana M (8) Darville L (9) Fang B (10) Rix U (11) Yoder S (12) Berglund A (13) Koomen JM (14) Haura EB (15) Abate-Daga D
(1) Ramello MC (2) Benzaid I (3) Kuenzi BM (4) Lienlaf-Moreno M (5) Kandell WM (6) Santiago DN (7) Pabon-Saldana M (8) Darville L (9) Fang B (10) Rix U (11) Yoder S (12) Berglund A (13) Koomen JM (14) Haura EB (15) Abate-Daga D
Author Info: (1) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (2) Department of Immunology, H. Lee Moffitt Cancer Center
Author Info: (1) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (2) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (3) Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33620, USA. (4) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (5) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33620, USA. (6) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (7) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (8) Proteomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (9) Proteomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (10) Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (11) Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (12) Department of Bioinformatics and Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (13) Proteomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (14) Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. (15) Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. daniel.abatedaga@moffitt.org. Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA.
Citation: Sci Signal 2019 Feb 12 12: Epub02/12/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30755478
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
(1) Schalper KA (2) Rodriguez-Ruiz ME (3) Diez-Valle R (4) Lopez-Janeiro A (5) Porciuncula A (6) Idoate MA (7) Inoges S (8) de Andrea C (9) Lopez-Diaz de Cerio A (10) Tejada S (11) Berraondo P (12) Villarroel-Espindola F (13) Choi J (14) Gurpide A (15) Giraldez M (16) Goicoechea I (17) Gallego Perez-Larraya J (18) Sanmamed MF (19) Perez-Gracia JL (20) Melero I
(1) Schalper KA (2) Rodriguez-Ruiz ME (3) Diez-Valle R (4) Lopez-Janeiro A (5) Porciuncula A (6) Idoate MA (7) Inoges S (8) de Andrea C (9) Lopez-Diaz de Cerio A (10) Tejada S (11) Berraondo P (12) Villarroel-Espindola F (13) Choi J (14) Gurpide A (15) Giraldez M (16) Goicoechea I (17) Gallego Perez-Larraya J (18) Sanmamed MF (19) Perez-Gracia JL (20) Melero I
Author Info: (1) Department of Pathology, Yale School of Medicine, New Haven, CT, USA. (2) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. Centro de Investigacion
Author Info: (1) Department of Pathology, Yale School of Medicine, New Haven, CT, USA. (2) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. Centro de Investigacion Biomedica en Red de Oncologia (CIBERONC), Madrid, Spain. Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain. (3) Department of Neurosurgery, Clinica Universidad de Navarra, Pamplona, Spain. Department of Immunology, Clinica Universidad de Navarra, Pamplona, Spain. (4) Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain. (5) Department of Pathology, Yale School of Medicine, New Haven, CT, USA. (6) Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain. (7) Department of Immunology, Clinica Universidad de Navarra, Pamplona, Spain. (8) Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain. (9) Department of Immunology, Clinica Universidad de Navarra, Pamplona, Spain. (10) Department of Neurosurgery, Clinica Universidad de Navarra, Pamplona, Spain. (11) Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. (12) Department of Pathology, Yale School of Medicine, New Haven, CT, USA. (13) Department of Genetics, Yale School of Medicine, New Haven, CT, USA. (14) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. (15) Department of Pharmacy, Clinica Universidad de Navarra, Pamplona, Spain. (16) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. (17) Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain. (18) Department of Pathology, Yale School of Medicine, New Haven, CT, USA. Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. (19) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain. Centro de Investigacion Biomedica en Red de Oncologia (CIBERONC), Madrid, Spain. Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain. (20) Centro de Investigacion Biomedica en Red de Oncologia (CIBERONC), Madrid, Spain. imelero@unav.es. Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain. imelero@unav.es. Department of Neurosurgery, Clinica Universidad de Navarra, Pamplona, Spain. imelero@unav.es. Department of Immunology, Clinica Universidad de Navarra, Pamplona, Spain. imelero@unav.es.
Citation: Nat Med 2019 Feb 11 Epub02/11/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30742120
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
(1) Zhao J (2) Chen AX (3) Gartrell RD (4) Silverman AM (5) Aparicio L (6) Chu T (7) Bordbar D (8) Shan D (9) Samanamud J (10) Mahajan A (11) Filip I (12) Orenbuch R (13) Goetz M (14) Yamaguchi JT (15) Cloney M (16) Horbinski C (17) Lukas RV (18) Raizer J (19) Rae AI (20) Yuan J (21) Canoll P (22) Bruce JN (23) Saenger YM (24) Sims P (25) Iwamoto FM (26) Sonabend AM (27) Rabadan R
(1) Zhao J (2) Chen AX (3) Gartrell RD (4) Silverman AM (5) Aparicio L (6) Chu T (7) Bordbar D (8) Shan D (9) Samanamud J (10) Mahajan A (11) Filip I (12) Orenbuch R (13) Goetz M (14) Yamaguchi JT (15) Cloney M (16) Horbinski C (17) Lukas RV (18) Raizer J (19) Rae AI (20) Yuan J (21) Canoll P (22) Bruce JN (23) Saenger YM (24) Sims P (25) Iwamoto FM (26) Sonabend AM (27) Rabadan R
Author Info: (1) Department of Systems Biology, Columbia University, New York, NY, USA. Department of Biomedical Informatics, Columbia University, New York, NY, USA. (2) Department of Systems
Author Info: (1) Department of Systems Biology, Columbia University, New York, NY, USA. Department of Biomedical Informatics, Columbia University, New York, NY, USA. (2) Department of Systems Biology, Columbia University, New York, NY, USA. (3) Department of Pediatrics, Pediatric Hematology/Oncology/SCT, Columbia University Irving Medical Center, New York, NY, USA. (4) Department of Pediatrics, Pediatric Hematology/Oncology/SCT, Columbia University Irving Medical Center, New York, NY, USA. (5) Department of Systems Biology, Columbia University, New York, NY, USA. Department of Biomedical Informatics, Columbia University, New York, NY, USA. (6) Department of Systems Biology, Columbia University, New York, NY, USA. Department of Biomedical Informatics, Columbia University, New York, NY, USA. (7) Department of Pediatrics, Pediatric Hematology/Oncology/SCT, Columbia University Irving Medical Center, New York, NY, USA. (8) Department of Pediatrics, Pediatric Hematology/Oncology/SCT, Columbia University Irving Medical Center, New York, NY, USA. (9) Department of Neurosurgery, Columbia University, New York, NY, USA. (10) Department of Neurosurgery, Columbia University, New York, NY, USA. (11) Department of Systems Biology, Columbia University, New York, NY, USA. (12) Department of Systems Biology, Columbia University, New York, NY, USA. (13) Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. (14) Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. (15) Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. (16) Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. (17) Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. (18) Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. (19) Department of Neurological Surgery, Oregon Health & Sciences University, Portland, OR, USA. (20) Department of Biomedical Informatics, Columbia University, New York, NY, USA. (21) Department of Pathology and Cell Biology, Columbia University, New York, NY, USA. (22) Department of Neurosurgery, Columbia University, New York, NY, USA. (23) Department of Medicine, Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA. (24) Department of Biomedical Informatics, Columbia University, New York, NY, USA. (25) Department of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA. fi2146@cumc.columbia.edu. (26) Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Adam.Sonabend@nm.org. (27) Department of Systems Biology, Columbia University, New York, NY, USA. rr2579@cumc.columbia.edu. Department of Biomedical Informatics, Columbia University, New York, NY, USA. rr2579@cumc.columbia.edu.
Citation: Nat Med 2019 Feb 11 Epub02/11/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30742119
Landscape of B cell immunity and related immune evasion in human cancers
(1) Hu X (2) Zhang J (3) Wang J (4) Fu J (5) Li T (6) Zheng X (7) Wang B (8) Gu S (9) Jiang P (10) Fan J (11) Ying X (12) Zhang J (13) Carroll MC (14) Wucherpfennig KW (15) Hacohen N (16) Zhang F (17) Zhang P (18) Liu JS (19) Li B (20) Liu XS
(1) Hu X (2) Zhang J (3) Wang J (4) Fu J (5) Li T (6) Zheng X (7) Wang B (8) Gu S (9) Jiang P (10) Fan J (11) Ying X (12) Zhang J (13) Carroll MC (14) Wucherpfennig KW (15) Hacohen N (16) Zhang F (17) Zhang P (18) Liu JS (19) Li B (20) Liu XS
Author Info: (1) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. (2) Center for Computational Biology, Beijing
Author Info: (1) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. (2) Center for Computational Biology, Beijing Institute of Basic Medical Sciences, Beijing, China. (3) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. (4) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. (5) State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China. (6) Department of Mathematics, Shanghai Normal University, Shanghai, China. (7) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. (8) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. (9) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. (10) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. (11) Center for Computational Biology, Beijing Institute of Basic Medical Sciences, Beijing, China. (12) Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. (13) Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. (14) Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. (15) Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. (16) Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. (17) Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. (18) Department of Statistics, Harvard University, Cambridge, MA, USA. jliu@stat.harvard.edu. (19) Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA. bo.li@utsouthwestern.edu. (20) Department of Data Sciences, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA. xsliu@jimmy.harvard.edu. Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China. xsliu@jimmy.harvard.edu. Department of Statistics, Harvard University, Cambridge, MA, USA. xsliu@jimmy.harvard.edu.
Citation: Nat Genet 2019 Feb 11 Epub02/11/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30742113
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma
(1) Blair AB (2) Kleponis J (3) Thomas Ii DL (4) Muth ST (5) Murphy AG (6) Kim V (7) Zheng L
(1) Blair AB (2) Kleponis J (3) Thomas Ii DL (4) Muth ST (5) Murphy AG (6) Kim V (7) Zheng L
Citation: J Clin Invest 2019 Feb 12 Epub02/12/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30747725
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
(1) Gide TN (2) Quek C (3) Menzies AM (4) Tasker AT (5) Shang P (6) Holst J (7) Madore J (8) Lim SY (9) Velickovic R (10) Wongchenko M (11) Yan Y (12) Lo S (13) Carlino MS (14) Guminski A (15) Saw RPM (16) Pang A (17) McGuire HM (18) Palendira U (19) Thompson JF (20) Rizos H (21) Silva IPD (22) Batten M (23) Scolyer RA (24) Long GV (25) Wilmott JS
(1) Gide TN (2) Quek C (3) Menzies AM (4) Tasker AT (5) Shang P (6) Holst J (7) Madore J (8) Lim SY (9) Velickovic R (10) Wongchenko M (11) Yan Y (12) Lo S (13) Carlino MS (14) Guminski A (15) Saw RPM (16) Pang A (17) McGuire HM (18) Palendira U (19) Thompson JF (20) Rizos H (21) Silva IPD (22) Batten M (23) Scolyer RA (24) Long GV (25) Wilmott JS
Author Info: (1) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. (2) Melanoma
Author Info: (1) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. (2) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. (3) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia; Department of Medical Oncology, Mater Hospital, North Sydney, NSW 2060, Australia. (4) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia. (5) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia. (6) Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Centenary Institute, The University of Sydney, Sydney, NSW 2050, Australia. (7) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia. (8) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia. (9) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia. (10) Oncology Biomarker Development, Genentech Inc, South San Francisco, CA 94080, USA. (11) Oncology Biomarker Development, Genentech Inc, South San Francisco, CA 94080, USA. (12) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia. (13) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, NSW 2145, Australia. (14) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia; Department of Medical Oncology, Mater Hospital, North Sydney, NSW 2060, Australia. (15) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. (16) Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Centenary Institute, The University of Sydney, Sydney, NSW 2050, Australia. (17) Ramaciotti Facility for Human Systems Biology, Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia. (18) Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Centenary Institute, The University of Sydney, Sydney, NSW 2050, Australia. (19) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. (20) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia. (21) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. (22) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. (23) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. (24) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia; Department of Medical Oncology, Mater Hospital, North Sydney, NSW 2060, Australia. (25) Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: james.wilmott@melanoma.org.au.
Citation: Cancer Cell 2019 Feb 11 35:238-255.e6 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30753825
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
(1) Du H (2) Hirabayashi K (3) Ahn S (4) Kren NP (5) Montgomery SA (6) Wang X (7) Tiruthani K (8) Mirlekar B (9) Michaud D (10) Greene K (11) Herrera SG (12) Xu Y (13) Sun C (14) Chen Y (15) Ma X (16) Ferrone CR (17) Pylayeva-Gupta Y (18) Yeh JJ (19) Liu R (20) Savoldo B (21) Ferrone S (22) Dotti G
(1) Du H (2) Hirabayashi K (3) Ahn S (4) Kren NP (5) Montgomery SA (6) Wang X (7) Tiruthani K (8) Mirlekar B (9) Michaud D (10) Greene K (11) Herrera SG (12) Xu Y (13) Sun C (14) Chen Y (15) Ma X (16) Ferrone CR (17) Pylayeva-Gupta Y (18) Yeh JJ (19) Liu R (20) Savoldo B (21) Ferrone S (22) Dotti G
Author Info: (1) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (2) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Author Info: (1) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (2) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (3) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA. (4) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. (5) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. (6) Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (7) Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. (8) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. (9) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC 27599, USA. (10) Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. (11) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (12) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (13) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (14) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (15) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. (16) Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (17) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. (18) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA. (19) Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA; Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, NC 27599, USA. (20) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599, USA. (21) Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (22) Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: gdotti@med.unc.edu.
Citation: Cancer Cell 2019 Feb 11 35:221-237.e8 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30753824
A T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targets human breast cancer
(1) Iizuka A (2) Nonomura C (3) Ashizawa T (4) Kondou R (5) Ohshima K (6) Sugino T (7) Mitsuya K (8) Hayashi N (9) Nakasu Y (10) Maruyama K (11) Yamaguchi K (12) Akiyama Y
(1) Iizuka A (2) Nonomura C (3) Ashizawa T (4) Kondou R (5) Ohshima K (6) Sugino T (7) Mitsuya K (8) Hayashi N (9) Nakasu Y (10) Maruyama K (11) Yamaguchi K (12) Akiyama Y
Author Info: (1) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (2) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (3) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (4)
Author Info: (1) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (2) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (3) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (4) Immunotherapy Division, Shizuoka Cancer Center Research Institute. (5) Medical Genetics Division, Shizuoka Cancer Center Institute. (6) Pathology, Fukushima Medical University. (7) Division of Neurosurgery, Shizuoka Cancer Center Hospital. (8) Division of Neurosurgery, Shizuoka Cancer Center Hospital. (9) Neurosurgery, Shizuoka Cancer Center. (10) Experimental Animal Facility, Shizuoka Cancer Center Research Institute. (11) Office of the President, Shizuoka Cancer Center. (12) Immunotherapy Division, Shizuoka Cancer Center Research Institute y.akiyama@scchr.jp.
Citation: Clin Cancer Res 2019 Feb 8 Epub02/08/2019
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/30737243